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INTRODUCTION
Eosinophilic granulomatosis with polyangiitis (eGPA) is a
small- and medium-sized-vessel vasculitis with multi-organ
manifestations. Given the rarity of eGPA, patients are
often misdiagnosed for decades and may initially present
with life-threatening manifestations of late-stage disease.
Therefore, it is important to raise awareness of this
condition and its associated signs and symptoms. This
case report serves to describe a classic presentation of a
patient with eGPA, as well as to delineate the diagnostic
workup, acute management, and early outpatient
follow-up required.

CASE PRESENTATION
A 57-year-old male with a history of recently-diagnosed
asthma (on chronic prednisone) presented to the
emergency department at our hospital with a month-long
history of shortness of breath and fatigue. He denied
wheezing and chest tightness typical of his asthma flares,
insisting that this isolated dyspnea was similar to the
symptoms he experienced two months earlier when he
presented to an outside hospital and was diagnosed with
symptomatic anemia.
He reported that he was in perfect health until one year
prior to presentation when he developed progressively
worsening respiratory symptoms. After evaluation by a
pulmonologist, he was started on budesonide-formoterol
twice daily in conjunction with his rescue inhaler. However,
he had persistent symptoms over the subsequent six
months, so was ultimately started on prednisone 30 mg
PO daily. At the time, he was noted to have an elevated IgE
and eosinophil count of 104 IU/mL and 900 cells/uL,
respectively. Though he improved dramatically with the

1A

addition of systemic steroids, he began to develop
generalized fatigue, weakness, chills, night sweats, and
migratory polyarthralgias a couple months later. His
primary care physician suspected Lyme disease and started
doxycycline without symptomatic improvement. He began
taking ibuprofen several times a day for the diffuse joint
pains. As the patient’s shortness of breath and fatigue
worsened, a complete blood count was obtained, and his
hemoglobin was found to be 6 g/dL. He was admitted to
an outside hospital where he received a blood transfusion
and underwent an upper endoscopy and colonoscopy
which did not demonstrate active bleeding. He was
discharged with instructions to avoid further NSAID use.
In the emergency department at our hospital, his
hemoglobin was 7.4 g/dL so he received a blood transfusion
for symptomatic anemia, which was suspected to be due
to an upper gastrointestinal bleed caused by NSAID- and
steroid-induced peptic ulcer disease. His chest x-ray
demonstrated patchy bilateral airspace opacities
throughout both lung fields concerning for multifocal
pneumonia. He was also started on ceftriaxone in
conjunction with his ongoing doxycycline therapy for
treatment of superimposed community-acquired
pneumonia. One hour after receiving one unit of blood,
the patient developed increased work of breathing with
hypoxia that did not improve with diuresis. A computed
tomography (CT) scan of the chest without contrast was
ordered to delineate possible hemorrhage or atypical
infection contributing to his deteriorating presentation. It
demonstrated multifocal airspace opacities in a
peri-bronchial vascular distribution with relative sparing of
the left lower lobe and subpleural spaces, findings
consistent with diffuse alveolar hemorrhage (DAH)” and
noncardiogenic pulmonary edema (Figure 1).
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Figure 1. Images from the
patient’s CT scan of the chest
demonstrates multifocal
airspace opacities in a
peri-bronchial vascular
distribution with relative
sparing of the left lower lobe
and subpleural spaces.
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The patient’s systemic symptoms and imaging was
suspicious for an underlying vasculitis complicated by
diffuse alveolar hemorrhage and gastroenteritis. He
underwent bronchoscopy which demonstrated diffuse
bloody secretions in the right upper lobe and lateral
basilar segment of the right lower lobe. Cytology
demonstrated marked acute inflammation with no
evidence of infection. Differential cell count did not
demonstrate eosinophils as would be expected in eGPA,
but this may be related to the patient’s chronic steroid
use pre-procedure. Laboratory studies were significant
for positive C-ANCA and PR-3 antibody with a titer of 4.3.
In conjunction with the patient’s elevated IgE and
eosinophilia from six months earlier, this lab work helped
to confirm the patient’s suspected diagnosis of eGPA.
On further discussion, the patient acknowledged that
he had experienced recurrent sinusitis and exerciseinduced asthma for one decade prior to initial
presentation. His sporadic episodes were managed
by his primary care physician until one year prior
to admission when he sought evaluation by a
pulmonologist and was ultimately started on chronic
prednisone, which alleviated his respiratory symptoms
and likely palliated his underlying vasculitis.

OUTCOME
The patient was pulsed with intravenous methylprednisolone 1 gram daily for 3 days, followed by oral
prednisone 1 mg/kg daily. He also received his first dose
of rituximab with the remaining three weekly infusions
to be scheduled as an outpatient, and two sessions of
inpatient plasmapheresis given his diffuse alveolar
hemorrhage. These interventions resulted in prompt
alleviation of his respiratory symptoms and migratory
polyarthralgias, and he was weaned to room air prior to
discharge. Six months after discharge, his prednisone
has been tapered to 40 mg daily, his repeat CT scan of
the chest demonstrates resolution of focal airspace
opacities initially observed in the setting of DAH, and his
PR-3 antibody titer is negative.

DISCUSSION
eGPA is characterized by the histological findings of
necrotizing vasculitis as well as eosinophilic infiltrates and
granulomas in tissues. 1 The American College of
Rheumatology has since defined six diagnostic criteria, of
which four should be present in a patient with suspected
eGPA: asthma, greater than 10% peripheral eosinophilia,
neuropathy, non-fixed pulmonary infiltrates, paranasal
sinus abnormalities, and extravascular eosinophils. Our
patient had a long history of recurrent sinusitis and asthma
prior to presentation, eosinophilia, and pulmonary
infiltrates. The disease progresses over the course of
decades, classified into three distinct phases: the

prodromal phase that is associated with allergic rhinitis
and asthma; eosinophilic infiltration of multiple organs
including the lungs and gastrointestinal tract; and granulomatosis resulting in life-threatening disease.2
Clinical presentations of eGPA differ based on associated
ANCA positivity. ANCA-negative patients typically present
with more frequent cardiomyopathy, while ANCA-positive
patients present with mononeuritis multiplex and glomerulonephritis. Poorer prognoses can be anticipated for
patients with documented gastrointestinal, renal, or
cardiac manifestations of the disease, meriting screening
endoscopies, urinalyses, and transthoracic echocardiograms of in-patients with newly-diagnosed eGPA. 3
Commonly noted laboratory abnormalities include serum
eosinophilia, elevated IgE levels, and P-ANCA of anti-MPO
specificity. However, up to 40% of patients with eGPA
demonstrate positive C-ANCA of anti-PR-3 specificity.
Extravascular eosinophilia (e.g. in bronchoalveolar lavage
fluid) and biopsy demonstrating granulomas aid in
confirming the diagnosis of eGPA. Despite these objective
features, eGPA is essentially a clinical diagnosis based on
symptom presentation and the presence of eosinophilia.
Recommendations on treatment of eGPA depend on the
severity of disease and organ involvement. Glucocorticoids
are first-line treatment for eGPA and those with severe
documented gastrointestinal, renal, pulmonary, or
cardiac involvement should be prescribed an additional
immunosuppressant (e.g. rituximab, cyclophosphamide).
Though plasma exchange is not merited for every patient
with newly-diagnosed eGPA, it may successfully forestall
progressive glomerulonephritis in ANCA-positive patients
with severe diffuse alveolar hemorrhage and renal
insufficiency.

KEY POINTS
Given the life-threatening complications of this rare
condition, it is important to raise awareness about eGPA.
This is a classic presentation of eGPA in a patient with a
decades-long asthma history, eosinophilia, new lung and
gastrointestinal manifestations, and systemic symptoms.
His serologies were significant for positive C-ANCA of
anti-PR-3 specificity. His clinical course included screening
for gastrointestinal, renal, and cardiac involvement as well
as initiating steroid therapy, plasmapheresis, and rituximab.
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